Month: October 2026
Form S-3 Eligibility: Cooley Obtains Novel SEC Staff Interpretive Guidance Updating and Extending Lamar Advertising Framework
By John-Paul Motley and Justin Kisner On October 26, 2026, the SEC’s Division of Corporation Finance staff issued interpretive guidance to Cooley client Sumisho Air Lease that updates and extends the framework established in the Lamar Advertising no-action letter (Nov. 18, 1996) governing Form S-3 eligibility during a brief voluntary […]
Choosing a Corporate Home: What We Learned From the 2026 Proxy Season
By Kealan Santistevan, Michael Mencher, Liz Dunshee and Vince Flynn This is the second post in our series on choosing where to incorporate. Part 1 looked at the trade-offs among Delaware, Nevada and Texas for founder-led technology companies. This post provides a bigger picture look at how market practice is […]
SEC Enforcement Update: SEC and FDA Formalize Information-Sharing Framework
By Liz Dunshee If you’re leading a publicly traded life sciences company, you are likely well aware of the complexities of navigating multiple regulators, with the Securities and Exchange Commission and the Food and Drug Administration playing major roles in the US. Those agencies don’t operate in a vacuum. The […]